Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abatacept for Recurrent or de Novo Autoimmune Hepatitis
NCT04203875Phase 1Terminated
- Start
- Mar 2020
- Primary completion
- Jul 2020
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of abatacept in autoimmune hepatitis (AIH). Primary endpoints: Number of Adverse Events, Number of Infections and 1 more. Started Mar 2020; status: terminated.
02
Drugs
abatacept
03
Conditions
autoimmune hepatitis (AIH)
Beyond the preview
Go deeper on NCT04203875.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04203875.